Itepekimab COPD Phase III — PatSnap Eureka
Itepekimab COPD Phase III: AERIFY-1/2 & Competitive Landscape vs. Dupilumab
Itepekimab (REGN3500/SAR440340), a fully human monoclonal antibody targeting IL-33, and dupilumab (anti-IL-4Rα) represent a converging type 2 inflammatory pathway strategy in COPD — a high-unmet-need indication lacking approved biologic therapies targeting upstream alarmin biology.
Why IL-33 Is a Compelling COPD Target
IL-33 functions as a damage-associated molecular pattern (DAMP) released by airway epithelium upon cigarette smoke or pathogen insult. This upstream alarmin signal activates ST2+ mast cells, ILC2s, and eosinophils — the key effector cells driving COPD exacerbation biology. Blocking IL-33 at this proximal step is the mechanistic rationale for itepekimab (REGN3500/SAR440340), a fully human monoclonal antibody developed by Sanofi and Regeneron's life sciences pipeline.
Unlike downstream cytokine blockade, targeting IL-33 intercepts the alarmin cascade before it amplifies type 2 inflammation. This positions itepekimab as a potential first-in-class anti-IL-33 therapy for COPD — an indication that has historically lacked approved biologic therapies targeting upstream alarmin biology. The NIH and academic consortia have highlighted alarmin biology as a critical frontier in COPD immunology.
COPD remains a high-unmet-need indication. The World Health Organization identifies COPD as the third leading cause of death globally, with existing pharmacological options providing symptom control rather than disease modification. The absence of approved biologics targeting the IL-33/ST2 axis represents a significant clinical gap that the AERIFY program seeks to address. Explore the full IP landscape with PatSnap Eureka's drug intelligence platform.
IL-33 Pathway & Biomarker Stratification
The IL-33/ST2 cascade from airway insult to exacerbation, and the biomarker toolkit used to enrich patient populations in COPD biologic trials.
IL-33/ST2 Activation Cascade in COPD
Sequential steps from airway epithelial insult to COPD exacerbation via the IL-33/ST2 alarmin pathway targeted by itepekimab.
Biomarker Stratification Tools: COPD Biologic Trials
Blood eosinophil counts, periostin, and FeNO are the three primary predictive enrichment biomarkers used across both the itepekimab and dupilumab COPD programs.
AERIFY-1/2 vs. BOREAS/NOTUS: Program Design
Both programs share a former-smoker COPD population and exacerbation-rate primary endpoints, but diverge in upstream vs. downstream mechanistic targeting of the type 2 pathway.
AERIFY-1 & AERIFY-2
Phase III trials evaluating itepekimab (REGN3500/SAR440340) in COPD. Patient selection criteria include former smokers and eosinophil thresholds. The primary endpoints focus on the annualized rate of moderate-to-severe COPD exacerbations, with key secondary endpoints also assessed. Itepekimab targets IL-33 at the upstream alarmin level, prior to ST2 receptor engagement.
Anti-IL-33 · Upstream alarmin blockadeBOREAS & NOTUS
The dupilumab BOREAS/NOTUS program evaluates anti-IL-4Rα blockade in COPD, addressing overlapping but mechanistically distinct type 2 signaling relative to IL-33 blockade. Dupilumab simultaneously blocks both IL-4 and IL-13 signaling through the shared IL-4Rα receptor subunit, generating regulatory momentum in the same COPD patient population as itepekimab.
Anti-IL-4Rα · IL-4 & IL-13 dual blockadeFormer Smoker COPD with Eosinophilia
Both programs enrich for former smokers with elevated blood eosinophil counts — a biomarker-defined subpopulation where type 2 inflammatory biology is most active. This shared patient selection strategy reflects the convergence of both programs on the eosinophilic COPD endotype, even as their mechanistic targets differ.
Former smokers · Eosinophil threshold selectionAnnualized Exacerbation Rate Reduction
Both AERIFY and BOREAS/NOTUS use the annualized rate of moderate-to-severe COPD exacerbations as the primary endpoint — the regulatory gold standard for COPD trials. This shared endpoint architecture enables direct comparison of efficacy signals across the two programs, informing the competitive positioning question of complementary vs. overlapping label claims.
Moderate-to-severe exacerbation rate · Primary endpointItepekimab vs. Dupilumab: Mechanistic & Strategic Comparison
A structured comparison of the two Sanofi/Regeneron COPD biologic programs, plus the broader competitive context including AstraZeneca and GSK.
| Attribute | Itepekimab (REGN3500) | Dupilumab | Competitive Context |
|---|---|---|---|
| Mechanism | Anti-IL-33 | Anti-IL-4Rα | Upstream vs. downstream type 2 blockade |
| Pathway Position | Alarmin (epithelial DAMP) | Shared receptor subunit | IL-33 is more proximal in the cascade |
| Cytokines Blocked | IL-33 → ST2 signaling | IL-4 + IL-13 (dual) | Dupilumab has broader cytokine coverage |
| Phase III Trials | AERIFY-1, AERIFY-2 | BOREAS, NOTUS | Both programs in same patient population |
| IP Strategy | Composition-of-matter patents; ST2 decoy receptor strategies | Broad IL-4Rα antibody claims | AstraZeneca, GSK filing competing patents |
| Competitive Positioning | Complementary or competing? | Overlapping label claims possible | Ex-asthma COPD biologics market |
Map the Full COPD Biologic Patent Landscape
Explore Regeneron/Sanofi composition-of-matter filings, ST2 decoy strategies, and competing AstraZeneca and GSK patent activity with PatSnap Eureka.
Anti-IL-33 COPD IP Landscape: Key Filing Strategies
The IP landscape spans Regeneron/Sanofi composition-of-matter patents, ST2 decoy receptor strategies, and competing filings from AstraZeneca and GSK across US, EP, and WO jurisdictions (2018–2025).
Regeneron/Sanofi Anti-IL-33 Composition-of-Matter Patents
The core IP estate for itepekimab includes anti-IL-33 antibody composition-of-matter patents protecting the REGN3500/SAR440340 molecule. These filings span US, EP, and WO jurisdictions from 2018–2025, establishing the foundational exclusivity position for a potential first-in-class COPD biologic. Access the full filing history via PatSnap's IP analytics platform.
ST2 Decoy Receptor Strategies
Beyond antibody composition claims, the IP landscape includes ST2 decoy receptor strategies — soluble ST2 fusion proteins designed to sequester IL-33 before it reaches membrane-bound ST2. These represent alternative approaches to IL-33 pathway blockade and are relevant to freedom-to-operate analysis for any entrant into the anti-IL-33 COPD space.
What a Complete AERIFY/BOREAS Analysis Covers
A comprehensive intelligence report on itepekimab and dupilumab in COPD would address six core analytical dimensions — from upstream biology through to competitive market implications. PatSnap's life sciences intelligence platform is purpose-built to deliver this depth of analysis across patent, literature, and clinical data sources.
- IL-33/ST2 axis biology — DAMP release, ST2+ effector cell activation, COPD exacerbation mechanisms
- AERIFY-1/2 trial design — patient selection, eosinophil thresholds, primary and secondary endpoints
- Dupilumab BOREAS/NOTUS comparative architecture — overlapping vs. distinct type 2 signaling
- IP landscape — composition-of-matter patents, ST2 decoy strategies, AstraZeneca and GSK competing filings
- Biomarker stratification — blood eosinophil counts, periostin, FeNO as predictive enrichment tools
- Competitive implications — complementary vs. competing asset positioning in ex-asthma COPD biologics
The PatSnap customer network includes leading biopharma R&D teams using Eureka to accelerate exactly this type of multi-dimensional competitive intelligence. Patent databases covering US, EP, and WO jurisdictions (2018–2025) alongside PubMed/MEDLINE literature and preprint servers are all accessible within a single platform. The European Patent Office is a key jurisdiction for Regeneron/Sanofi anti-IL-33 filings.
Itepekimab COPD Phase III — key questions answered
Itepekimab (REGN3500/SAR440340) is a fully human monoclonal antibody targeting interleukin-33 (IL-33), developed by Sanofi and Regeneron. It is being investigated as a potential first-in-class anti-IL-33 therapy for COPD, representing an upstream alarmin biology approach to type 2 inflammatory pathway blockade.
AERIFY-1 and AERIFY-2 are Phase III clinical trials evaluating itepekimab in COPD. Patient selection criteria include former smokers and eosinophil thresholds. The primary endpoints focus on the annualized rate of moderate-to-severe COPD exacerbations, with key secondary endpoints also assessed.
Itepekimab targets IL-33 (an upstream alarmin), while dupilumab targets IL-4Rα, blocking both IL-4 and IL-13 signaling. Both address overlapping but mechanistically distinct type 2 inflammatory pathways in COPD. The question of whether they are complementary (different patient subsets) or competing (overlapping label claims) assets in the ex-asthma COPD biologics market remains a key competitive consideration.
IL-33 functions as a damage-associated molecular pattern (DAMP) released by airway epithelium upon cigarette smoke or pathogen insult. It activates ST2+ mast cells, ILC2s, and eosinophils, playing a role in COPD exacerbation biology.
Blood eosinophil counts, periostin, and FeNO (fractional exhaled nitric oxide) are identified as predictive enrichment tools used as biomarker stratification strategies across both the itepekimab and dupilumab COPD programs.
The IP landscape includes Regeneron/Sanofi anti-IL-33 antibody composition-of-matter patents, ST2 decoy receptor strategies, and competing filings from AstraZeneca (tezepelumab-adjacent programs) and GSK, spanning US, EP, and WO jurisdictions from 2018 to 2025.
Still have questions about itepekimab, IL-33, or COPD biologic intelligence?
Ask PatSnap Eureka InstantlyAccelerate Your COPD Biologic Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map drug pipelines, decode IP landscapes, and track competitive biologics programs in real time.
References
- World Health Organization — COPD as the third leading cause of death globally
- National Institutes of Health — IL-33 alarmin biology and COPD immunology research
- European Patent Office — Anti-IL-33 and anti-IL-4Rα patent filings (US, EP, WO jurisdictions 2018–2025)
- ClinicalTrials.gov — AERIFY-1, AERIFY-2, BOREAS, NOTUS Phase III trial registrations
- bioRxiv / medRxiv — Preprint literature on AERIFY readout data and COPD biologic programs
- PubMed/MEDLINE — Clinical trial publications and review articles on IL-33/ST2 axis in COPD
All data and analysis on this page are derived from the source content and from PatSnap's proprietary innovation intelligence platform. Patent and literature retrieval for full citation-anchored analysis is available via PatSnap Eureka.
PatSnap Eureka searches patents and research to answer instantly.